- Email: [email protected]
Correction to Lancet Oncol 2016; 17: 1426
Corrections
Correction to Lancet Oncol 2016; 17: 738
Correction to Lancet Oncol 2016; 17: e310
Correction to Lancet Oncol 2016; 17: 1203, 06, 08, 09, 11
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-ofconcept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738–46— In this Article, Alberto Bardelli should have been marked as having contributed equally as a senior author. This correction has been made to the online version as of Oct 4, 2016.
Sauvaget C, Nishino Y, Konno R, et al. Challenges in breast and cervical cancer control in Japan. Lancet Oncol 2016; 17: e305–12—In the declaration of interests section of this Review, the declaration for RK should have included “and has received lecture fees from Japan Vaccine Co Ltd and MSD for lectures on the safety and effectiveness of the HPV vaccine.” This correction has been made to the online version as of Oct 4, 2016.
Wallington M, Saxon EB, Bomb M, et al. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol 2016; 17: 1203–16—This Article should have been published under the copyright “© The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license”. Also, in the “Patients with NSCLC” column in table 1 of this Article, and in the “30-day mortality” columns in tables 2, 3, 5 and 7 of this Article, some percentages were incorrect. These percentages have been updated. These corrections have been made to the online version as of Aug 31, 2016.
Correction to Lancet Oncol 2016; 17: 1426 Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17: 1426–34— The title of this Article should have stated that this study was open-label, not double-blind. This correction has been made to the online version as of Sept 1, 2016, and the printed version is correct.
www.thelancet.com/oncology Vol 17 October 2016
Correction to Lancet Oncol 2016; 17: e423 Burki TK. Arginine deprivation for ASS1-deficient mesothelioma. Lancet Oncol 2016; 17: e423—In this News item, the third sentence of the second paragraph should read “Moreover, the results showed that patients with ASS1 loss exceeding 75% received a greater benefit from arginine deprivation than those with ASS1 loss of 50–75% (PFS HR 0·25; 95% CI 0·09–0·70; vs HR 0·72; 95% CI 0·34–1·49; interaction p=0·21)”. This correction has been made to the online version as of Oct 4, 2016.
Published Online August 31, 2016 http://dx.doi.org/10.1016/ S1470-2045(16)30438-7
Published Online September 1, 2016 http://dx.doi.org/10.1016/ S14702045(16)30440-5
e420
Correction to Lancet Oncol 2016; 17: 738
Correction to Lancet Oncol 2016; 17: e310
Correction to Lancet Oncol 2016; 17: 1203, 06, 08, 09, 11
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-ofconcept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738–46— In this Article, Alberto Bardelli should have been marked as having contributed equally as a senior author. This correction has been made to the online version as of Oct 4, 2016.
Sauvaget C, Nishino Y, Konno R, et al. Challenges in breast and cervical cancer control in Japan. Lancet Oncol 2016; 17: e305–12—In the declaration of interests section of this Review, the declaration for RK should have included “and has received lecture fees from Japan Vaccine Co Ltd and MSD for lectures on the safety and effectiveness of the HPV vaccine.” This correction has been made to the online version as of Oct 4, 2016.
Wallington M, Saxon EB, Bomb M, et al. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol 2016; 17: 1203–16—This Article should have been published under the copyright “© The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license”. Also, in the “Patients with NSCLC” column in table 1 of this Article, and in the “30-day mortality” columns in tables 2, 3, 5 and 7 of this Article, some percentages were incorrect. These percentages have been updated. These corrections have been made to the online version as of Aug 31, 2016.
Correction to Lancet Oncol 2016; 17: 1426 Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17: 1426–34— The title of this Article should have stated that this study was open-label, not double-blind. This correction has been made to the online version as of Sept 1, 2016, and the printed version is correct.
www.thelancet.com/oncology Vol 17 October 2016
Correction to Lancet Oncol 2016; 17: e423 Burki TK. Arginine deprivation for ASS1-deficient mesothelioma. Lancet Oncol 2016; 17: e423—In this News item, the third sentence of the second paragraph should read “Moreover, the results showed that patients with ASS1 loss exceeding 75% received a greater benefit from arginine deprivation than those with ASS1 loss of 50–75% (PFS HR 0·25; 95% CI 0·09–0·70; vs HR 0·72; 95% CI 0·34–1·49; interaction p=0·21)”. This correction has been made to the online version as of Oct 4, 2016.
Published Online August 31, 2016 http://dx.doi.org/10.1016/ S1470-2045(16)30438-7
Published Online September 1, 2016 http://dx.doi.org/10.1016/ S14702045(16)30440-5
e420